Cellular Biomedicine Group, Inc.
DelistedCIK 1378624fmd_1W37T9GK5H564SX5RKKAPKYB7XManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2010 to Sep 30, 2020, 42 periods
| Line item | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 9 | 0 | 1 | 3 | 1 | 0 | 0 | 0 |
| Rental revenue | – | – | – | – | – | – | – | – | 2 | 3 |
| Cost of revenue | 0 | 0 | – | 0 | 0 | 2 | 1 | 0 | 0 | 0 |
| Gross profit | 2 | 0 | 9 | (0) | 0 | 1 | (0) | 0 | 0 | 0 |
| Realized investment gains (losses) | – | – | – | (0) | (0) | (0) | 0 | 0 | 0 | 0 |
| Research and development | – | – | 3 | 2 | 3 | 8 | 11 | 15 | 24 | 38 |
| Selling, general and administrative | 1 | 1 | 4 | 9 | 8 | 14 | 12 | 13 | 14 | 14 |
| Total operating expenses | 1 | 1 | 7 | 12 | 13 | 23 | 29 | 28 | 41 | 51 |
| Operating income | 0 | (1) | (7) | (11) | (12) | (21) | (28) | (28) | (41) | (51) |
| Interest expense | 0 | 0 | 0 | 0 | – | – | – | 0 | 0 | 0 |
| Interest and investment income | 0 | 0 | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (0) | 1 | 0 | (0) | 0 | 1 | 0 | 2 | 2 | 1 |
| Income before taxes | (0) | (1) | (7) | (11) | (12) | (20) | (28) | (25) | (39) | (50) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | (1) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (0) | (1) | (7) | (11) | (12) | (19) | (28) | (25) | (39) | (50) |
| Net income | (0) | (1) | (7) | (14) | (15) | (19) | (28) | (25) | (39) | (50) |